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A conjugate of pyridine-4-aldoxime and atropine (ATR-
4-OX) was synthesized and its antidotal efficiency was 
tested in vitro on tabun- or paraoxon-inhibited acetyl-
cholinesterase (AChE) of human erythrocytes as well 
as in vivo using soman-, tabun- or paraoxon-poisoned 
mice. Its genotoxic profile was assessed on human lym-
phocytes in vitro and was found acceptable for further 
research. ATR-4-OX showed very weak antidotal activity, 
inadequate for soman or tabun poisoning. Conversely, 
it was effective against paraoxon poisoning both in vit-
ro and in vivo. All animals treated with 5 % or 25 % LD50 
doses of the new oxime survived after administration of 
10.0 or 16.0 LD50 doses of paraoxon, respectively. Based 
on the persistence of toxicity symptoms in mice, the at-
ropine moiety had questionable effects in attenuating 
such symptoms. It appears that ATR-4-OX has a thera-
peutic effect related to the reactivation of phosphylated 
AChE, but not to receptor antagonization. 
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INTRODUCTION
Organophosphorus compounds (OP) inhibit acetylcho-
linesterase (AChE) by phosphylating its catalytic serine at 
the active site. AChE inhibition causes accumulation of 
neurotransmitter acetylcholine (ACh) at the synapses, re-
sulting in overstimulation of cholinergic receptors (Namba 
et al., 1971). Due to the high mortality rate of OP poi-
soning, early diagnosis and appropriate treatment are often 
life saving. The current regimen for treatment of OP poi-
soning consists primarily of atropine to block the effect of 
excess ACh at muscarinic receptors (i.e., nausea, vomiting, 
diarrhoea and bowel movements) and an oxime to reacti-
vate the inhibited AChE. Therapy with conventional ox-
imes, such as pralidoxime (2-PAM), trimedoxime (TMB-
4), asoxime (HI-6) and obidoxime (LüH-6), has disadvan-
tages either due to their inability to act as reactivators of 
AChE inhibited by some OP or due to their toxicity. The 
search for new potent reactivators led us to the synthesis 
of a conjugated compound based on three important frag-
ments: pyridine-4-aldoxime, a butylene chain and atropine. 
The oxime group at position four in the pyridinium ring 
and the butylene linker have been shown to be beneficial 
structural characteristics against inhibition by OP in previ-
ous studies (Pang et al., 2003; Kim et al., 2005; Antonijević 
& Stojiljković, 2007; Kovarik et al., 2007; Kovarik et al., 
2008; Kovarik et al., 2010). Furthermore, encouraged by 
the effectiveness of quaternized atropine as an antimus-
carinic drug (Sugai et al., 1985; Schmeller et al., 1995), we 
combined this moiety with the oxime to create a com-
pound that could potentially act as an antidote against OP 
poisoning. 
The newly synthesized compound ATR-4-OX was in-
vestigated in parallel for its potency to reactivate tabun- or 
paraoxon-inhibited human erythrocyte AChE and for its 
therapeutic efficacy in soman-, tabun- or paraoxon-poi-
soned mice. Based on previous findings of the acceptable 
cytotoxic and genotoxic profile of HI-6 oxime (Radić et 
al., 2007), we conducted the same tests for ATR-4-OX. 
MATERIALS AND METHODS
Synthesis. Design of the novel compound atropine-4-
pyridinealdoxime (ATR-4-OX) is shown in Fig. 1. Inter-
mediate 4-pyridinecarbaldehyde oxime (1) was prepared 
according to Poziomek et al. (1958). The key intermediate 
[8-(4-bromobutyl)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-
methyl-8-azoniabicyclo[3.2.1]octane bromide] (2) is quater-
nized atropine prepared by the described method, using 
atropine and dibromobutane in acetonitrile at room tem-
perature (Makarevich & Gubin, 2006). The crude inter-
mediate 2 containing the starting atropine was used in 
the following reaction without further purification. Bis-
quaternization with pyridine-4-aldoxime was achieved by 
reaction in acetonitrile at 80 °C for three days. Interme-
diates 2 (200 mg) and 1 (100 mg, 0.8 mmol) were dis-
solved in 10 ml of acetonitrile and stirred at 80 °C for 
three days. The solvent was then decanted and the resid-
ual brown oil was washed with acetonitrile (20 ml) and 
purified by preparative HPLC. The product obtained af-
ter purification was converted to dichloride salt by dis-
solution in HCl 6 M (5 ml) and lyophilization of the re-
sulting solution. ATR-4-OX [8-(4-{4-[(E)-(hydroxyimino)
methyl]-1-pyridiniumyl}butyl)-3-[(3-hydroxy-2-phenylpro-
panoyl)oxy]-8-methyl-8-azoniabicyclo [3.2.1]octane di-
chloride] (3) (104 mg, 0.19 mmol) was obtained in the 
form of a white, highly hygroscopic powder. The purity 
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of the compound was at least 96 %, as determined by 
HPLC.
All solvents used were dried using the appropriate 
well known methods. Chemicals were used as received 
from Sigma-Aldrich, Inc., Steinheim, Germany, unless 
otherwise stated. 1,4-dibromobutane was distilled under 
reduced pressure prior to use. Reactions were performed 
under an argon atmosphere.
The progression of reactions was monitored on an 
analytical UPLC-MS/UV spectrophotometer (Waters 
Ultra performance LC). All analyses were carried out at 
25 °C using a 2.1 mm × 50 mm, 1.7 µm, reversed pha-
se Waters Acquity UPLC BEH C18 column and a bi-
nary eluent made from solution A (0.1 % formic acid in 
water) and solution B (0.1 % formic acid in acetonitrile). 
This eluent was used as a gradient from 5 % of soluti-
on B to 90 % of solution B over 12 min. Flow rate was 
1 ml/min (all solvents were HPLC grade, Merck & Co., 
Inc., NJ, USA). The UPLC system was monitored with 
a DAD array detector at 254 nm and an SQD detector.
The final purity of the compounds was monitored 
on analytical HPLC-MS spectrophotometer (Waters 
2690). All analyses were carried out at 25 °C using a 
3 mm × 100 mm, 3.5 µm, reversed phase X-Terra C18 
column and a binary eluent made from solution A and 
the solution B. This eluent was used as a gradient from 
5 % of solution B to 90 % of solution B over 19.5 min. 
Flow rate was 0.5 ml/min. The HPLC system was mo-
nitored with a DAD array detector at 254 nm and a Mi-
cromass Quattromicro mass spectrometer.
HPLC-MS/UV purification was carried out at 25 °C on 
a Waters auto purification system using a 19 mm × 100 mm, 
5 µm reversed phase C18 X-Terra column and a binary elu-
ent made from solution A and solution B. This eluent was 
used as a gradient from 5 % of solution B to 30 % of solu-
tion B over 20 min. Flow rate was 20 ml/min.
NMR spectra were recorded for dilute solution in 
DMSO d6 at 298 K using a Bruker™ spectrometers 
(500 and 600 MHz). All NMR spectra were referenced 
to tetramethylsilane (TMS δH 0, δC 0). All coupling con-
stants are reported in Hertz (Hz), and multiplicities are 
labelled s (singlet), bs (broad singlet), d (doublet), t (trip-
let), q (quartet), dd (doublet of doublets).
Analytical and spectral data of intermediate 2: 
1H NMR (DMSO d6) δ ppm 1.67 (d, J = 16.92 Hz, 
1H), 1.73–1.88 (m, 5H), 2.08–2.14 (m, 2H), 2.09 (d, J 
= 9.59 Hz, 1H), 2.19 (d, J = 6.63 Hz, 1H), 2.51–2.57 
(m, 1H), 3.01 (s, 2H), 3.12–3.21 (m, 2H), 3.53-3.61 (m, 
2H), 3.68 (td, J = 10.29, 5.15 
Hz, 1H), 3.79 (dd, J = 8.81 
Hz, J = 5.50 Hz, 2H), 3.82-
3.86 (m, 1H), 3.97 (td, J = 
9.59 Hz,5.76Hz, 1H), 4.95-
5.02 (m,1H), 5.08 (t, J=4.97 
Hz,1H), 7.25–7.37 (m, 5H); 
ES+: 426 [M+1]
Analytical and spectral 
data of ATR-4-OX (3): 1H 
NMR (DMSO d6) δ ppm 
1.65–1.75 (m, 3H), 1.77–1.90 
(m, 2H), 1.90–1.99 (m, 2H), 
2.11 (d, J = 7.93 Hz, 2H), 
2.22 (d, J = 6.41 Hz, 1H), 
2.52–2.62 (m, 2H), 3.03 (s, 
3H), 3.18–3.27 (m, 3H), 3.69 
(dd, J = 10.38, 5.49 Hz, 1H), 
3.81 (dd, J = 8.85, 5.49 Hz, 
2H), 3.87 (d, J = 5.19 Hz, 
1H), 3.99 (t, J = 9.61 Hz, 
1H), 4.63 (t, J = 7.02 Hz, 2H), 7.27–7.38 (m, 5H), 8.25 
(d, J = 6.71 Hz, 2H), 8.45 (s, 1H), 9.06 (d, J = 6.41 Hz, 
2H); ES+: 466.35 [M+1], 233.71
Reactivation of tabun- or paraoxon-inhibited 
AChE. Tabun [ethyl N,N-dimethylphosphoroamidocya-
nidate] was purchased from NC Laboratory, Spiez, Swit-
zerland, and paraoxon (O,O-diethyl-O-(4-nitrophenyl)
phosphate) was purchased from Sigma Chemical Co., St. 
Louis, MO, USA. Enzyme substrate, acetylthiocholine io-
dide (ATCh), and thiol reagent, 5,5′-dithiobis(2-nitroben-
zoic acid) (DTNB) were also from Sigma. Native human 
non-haemolysed erythrocytes were the source of AChE. 
They were obtained after blood centrifugation (20 min, 
2500 rpm) and washing with sodium phosphate buffer 
(0.1 M, pH 7.4) to remove residual plasma. Final dilution 
of erythrocytes in the enzyme activity assay was 400-fold. 
Undiluted erythrocytes were incubated with 5 μM tabun 
or 1 μM paraoxon for about 60 min to achieve 95–100 % 
inhibition. The excess of organophosphorus compound 
was extracted with a 5-fold volume of hexane (De Jong 
et al., 1989). The inhibition mixture was diluted 10-times 
with sodium phosphate buffer (0.1 M, pH 7.4) contain-
ing ATR-4-OX to start the reactivation. Final ATR-4-OX 
concentrations used for the reactivation were 0.05, 0.2, 0.5 
and 1.0 mM in the case of tabun-inhibited, and 0.01, 0.03, 
0.05, 0.1, 0.2, 0.5 and 1.0 mM in the case of paraoxon-in-
hibited AChE. Reactivation of soman-inhibited AChE was 
not tested in vitro because of its fast aging (Worek et al., 
2004). Reactivation measurements were done at 25 °C on 
a CARY 300 spectrophotometer (Varian Inc., Australia). 
Detailed procedure of kinetic parameters determination 
was described previously (Čalić et al., 2006).
Studies in vivo. Male NIH/Ola Hsd mice (18–25 g 
body weight) were kept in Macrolone cages at 21 °C with 
12-h light and dark cycles. Animals were fed a standard 
diet (4RF21, Mucedola, Milano, Italy) with free access to 
water. In each of the in vivo experiments, 4 to 8 groups 
of 4 animals each were used.
Soman and tabun were purchased from NC Labo-
ratory, Spiez, Switzerland, while paraoxon was pur-
chased from Sigma Chemical Co., St. Louis, MO, 
USA. HI-6 [(1-(2-hydroxyiminomethylpyridinium)-3-(4-
carbamoylpyridinium)-2-oxapropane dichloride)] was 
synthesized in the Department of Toxicology, Faculty 
of Military Health Sciences, Hradec Kralove, Czech Re-
public. TMB-4 [1,3-bis(4-hydroxyiminomethylpyridinium) 
propane dibromide] was synthesized at Bosnalijek, Sara-
Figure 1. Design of the novel compound ATR-4-OX
(1) 4-pyridinecarbaldehyde oxime; (2) 8-(4-bromobutyl)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-
methyl-8-azoniabicyclo[3.2.1]octane bromide; (3) 8-(4-{4-[(E)-(hydroxyimino)methyl]-1-pyridiniumyl}
butyl)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-azoniabicyclo [3.2.1] octane dichloride
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jevo, Bosnia and Herzegovina. Atropine sulphate was 
purchased from Kemika, Zagreb, Croatia.
Acute toxicity (LD50) of ATR-4-OX was based on 
24 h mortality rates calculated according to Thompson 
(1947) and Weil (1952). LD50 was evaluated from the re-
sults obtained with four doses of ATR-4-OX (dissolved 
in water); four animals were injected per dose. 
The therapeutic effects against soman, tabun or pa-
raoxon intoxication were tested by administering ATR-
4-OX alone or with atropine sulphate (10.0 mg/kg), 
immediately after OP. The currently used oximes HI-6 
and TMB-4 were included for comparison. All oximes 
were used at two different doses, 5 % and 25 % of their 
respective LD50. OP compounds were given subcutaneo-
usly (s.c.) while therapy was administered intraperitone-
ally (i.p.). Mice were observed for 24 h and the antidotal 
efficacy of compounds was expressed as the protective 
index (PI) and maximal dose of poison (MDP). PI was 
calculated as the ratio of LD50 between OP with antidote 
and LD50 of OP in non-treated mice. The MDP was the 
highest multiple of the LD50 of OP that was fully coun-
teracted (survival of all animals) by the antidotes.
This study was performed with the approval of the 
Ethics Committee of the Institute for Medical Research 
and Occupational Health in Zagreb, Croatia.
Assessment of genotoxicity on human lym-
phocytes. A blood sample was obtained from a healthy 
male donor (age 34 years, non-smoker) who gave his in-
formed consent for participation in the study. The donor 
had not been exposed to diagnostic or therapeutic irra-
diations or to known genotoxic chemicals for one year 
before blood sampling. Venous blood (20 ml) was col-
lected under sterile conditions in vacutainer tubes (BD 
Vacutainer® REF 367883, V = 4 ml; Becton Dickinson, 
Franklin Lakes, NJ, USA) containing lithium heparin 
(LH 68 I.U.) as an anticoagulant. 
Lymphocyte isolation was performed as described 
elsewhere (Kopjar et al., 2007). Lymphocyte samples 
were incubated for 30 min in RPMI culture medium 
(Gibco) in vitro: (1) with ATR-4-OX, (2) with ATR-4-OX 
in the presence of S9 fraction (10 %, v/v; Sigma-Aldrich 
Product Number S 2442) as the metabolic activator, ac-
cording to the manufacturer’s instructions. Concentrati-
ons of ATR-4-OX were calculated from values of doses 
applied in in vivo experiments. Corresponding negative 
controls (with and without S9) were studied in parallel. 
Evaluation of cell viability and apoptosis/necrosis was 
performed immediately after the treatment using the dye 
exclusion method (Duke & Cohen, 1992). Three parallel 
tests with aliquots of the same sample were performed, 
and a total of 300 cells per sample were counted under a 
fluorescence microscope (Zeiss, Germany).
The comet assay was conducted under alkaline con-
ditions, as described by Singh et al. (1988), and in neu-
tral conditions according to Wojewódzka et al. (2002). 
Each slide was examined using a fluorescence micro-
scope (Zeiss, Germany) equipped with an excitation fil-
ter of 515–560 nm and a barrier filter of 590 nm. Us-
ing a black and white camera, the microscope image was 
transferred to a computer-based image analysis system 
(Comet Assay II, Perceptive Instruments Ltd., Suffolk, 
Halstead, UK). 
The hOGG1 assay was performed according to Smi-
th et al. (2006), and following the modified procedure 
described in Mladinić et al. (2009). We used commerci-
ally available hOGG1 FLARETM Assay Module (Trevi-
gen Inc., USA). Oxidative DNA damage was given as 
the difference between values obtained from slides trea-
ted with hOGG1 enzyme and the Flare reaction buffer 
only. The 25× Flare buffer consisted of 250 mM Hepes-
KOH, 250 mM EDTA and 2.5 M KCl, pH 7.4. Each 
slide was examined using a 250× magnification fluores-
cence microscope (Zeiss, Germany).
Statistical analyses. Statistical analyses were carried 
out with Statistica 5.0 (StatSoft, Tulsa, USA). In order to 
normalize distribution and equalize variances, a logarit-
hmic transformation of data was applied. The extent of 
DNA damage, as recorded by the alkaline and neutral co-
met assays, was analysed considering the mean (± stan-
dard error of the mean), median and range of the comet 
tail moment. Comparisons between samples were done 
using the one-way analysis of variance (ANOVA) and su-
bsequently the Duncan test was applied for calculations 
concerning pair-wise comparisons. For the hOGG1-modi-
fied comet assay, the mean tail length and tail intensity va-
lues were calculated for each replicate slide. Means obta-
ined with the buffer were compared with means for the 
corresponding enzyme-treated slide using the Wilcoxon 
Rank Sum Test. Comparisons between the values obtai-
ned for cell viability, apoptosis and necrosis in treated and 
control samples were conducted using the χ2 test. The le-
vel of statistical significance was set at p<0.05. 
RESULTS AND DISCUSSION
The aim of the present study was to evaluate the an-
tidotal potency against OP poisoning of a newly synt-
hesized compound in which an atropine-like moiety is 
coupled with a pyridinium oxime. Since atropine is the 
mainstay of supportive therapy, we wanted to find out 
if it would have an impact on the overall efficacy of the 
conjugated molecule, ATR-4-OX. 
We tested the potency of this new compound to re-
activate tabun- or paraoxon-inhibited human erythrocyte 
AChE. Reactivation of paraoxon-inhibited AChE was 
very efficient. AChE activity was completely restored 
after only 20 min, even when a low concentration of 
ATR-4-OX was applied. The overall reactivation rate 
constant for paraoxon, kr, was about 2000 min–1 M–1 
(Table 1). In contrast to paraoxon, ATR-4-OX was not 
efficient in reactivating tabun-inhibited AChE (kr = 67 
min–1 M–1). Its reactivation was slow and a maximum of 
90 % was obtained in 7 h (Table 1). It seems that the at-
ropine moiety did not affect the affinity for phosphylat-
ed AChE, since the dissociation constant, KOX, of about 
100 µM is similar to or even higher than that of HI-
6, 2-PAM or obidoxime (Worek et al., 2004). However, 
Table 1. ATR-4-OX assisted reactivation of tabun- or paraoxon-
inhibited human erythrocyte AChE
Tabun Paraoxon
ATR-4–OX (mM) 0.05–1.0 0.01–1.0
kmax (min–1) 0.008± 0.002 0.17 ± 0.02
KOX (mM) 0.12 ± 0.09 0.07 ± 0.03
kr (min–1 · M–1) 66.7 ± 52.7 2428 ± 1080
React.max ( %) 90 100
t 7 h 20 min
kmax, maximum first order reactivation rate constant; KOX, phosphylated 
enzyme-oxime dissociation constant; kr, overall reactivation rate con-
stant; React.max, maximal reactivation obtained in time t. Constants 
(± S.E.) were calculated from experimental data obtained in at least 
three experiments.  
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stabilisation of ATR-4-OX in tabun-inhibited AChE was 
non-productive, implying that nucleophilic displacement 
occurs at a very low rate (kmax for tabun and paraoxon-
inhibited AChE was 0.008 and 0.17 min–1, respectively). 
For comparison, the maximum reactivation constant, 
kmax, of the most efficient reactivator of tabun-inhibited 
AChE, K203, was 0.13 min–1 (Kovarik et al., 2009).
In vivo antidotal activity of the new compound was 
evaluated in the therapy of tabun, soman or paraoxon 
poisoning in mice. The tested oxime was toxic to mice; 
its LD50 was 10 mg/kg body weight, which is conside-
rably lower than that for HI-6 (635.2 mg/kg) or TMB-4 
(73.5 mg/kg) (Čalić et al., 2006). The first symptoms of 
the oxime toxicity appeared shortly after i.p. administra-
tion and some animals died very soon. Other mice par-
tially recovered at 24 h. Muscle fasciculation and tremor 
generally occurred within 5–10 min. Symptoms such as 
ataxia, dyspnoea, tremor, fasciculation, and salivation 
persisted for 30–60 min, after which all symptoms beca-
me more pronounced and persisted for up to 3 h, while 
tremor could be provoked for up to 24 h. Based on the 
persistence of toxicity symptoms in mice, it seems that 
the effects of the atropine moiety in attenuating such 
symptoms are questionable. 
Table 2 presents evaluated antidotal efficiency of ATR-
4-OX in soman, tabun and paraoxon poisoning applied 
at two doses. Severe signs of toxicity were observed in 
all animals despite antidotal treatment. Muscle fascicula-
tion and tremor generally occurred within 1–2 min after 
poisoning. Convulsions appeared with a latency of 3–4 
min. During the acute phase, all animals exhibited dys-
pnoea and cyanosis. Animals that survived remained ac-
tive for 24 h. Although ATR-4-OX is a conjugated com-
pound consisting of an atropine-like moiety, poisoning 
symptoms were not surpressed. In addition, survival ra-
tes after application of ATR-4-OX alone were very low 
in contrast to therapy with 
ATR-4-OX plus atropine 
(Table 2). This is in accord 
with previously published 
data which indicate that 
the application of conven-
tional oximes alone is not 
satisfactory (Bošković et al., 
1980; Bošković et al., 1984; 
Dawson, 1994). Also, it 
has previously been shown 
that after the administrati-
on of atropine alone, pro-
tective index (PI) is below 
2 in many cases (Dawson, 
1994). ATR-4-OX appli-
ed with atropine was very 
effective against paraoxon 
poisoning at both applied 
doses, showing survival of 
all animals after administra-
tion of 10.0 and 16.0 LD50 
doses of paraoxon. Howe-
ver, it showed weak antido-
tal activity for soman and 
tabun poisoning, especially 
in comparison with HI-6 
and TMB-4, respectively. 
Table 2. Effect of ATR-4-OXa with and without atropine compared to currently used oximesa HI-6 and TMB-4 upon (s.c.) somanb, 
tabunc and paraoxond toxicity in mice
OP
ATR-4-OX ATR-4-OX + atropine HI-6 + atropine TMB-4 + atropine
5 % LD50 25  % LD50 5 % LD50 25 % LD50 5 % LD50 25 % LD50 5 % LD50 25 % LD50
Soman
PI 1.5 1.2 1.5 1.2 3.2 4.7 – –
MDP 1.3 0.8 1.3 1.0 2.0 3.2 – –
Tabun
PI 1.7 2.8 2.3 2.4 –f – 8.9 7.1
MDP 1.3 2.0 2.0 2.0 – – 4.0 5.0
Paraoxon
PI nde 5.7 11.6 22.5 20.0 23.8 15.0 16.8
MDP nd 1.6 10.0 16.0 12.6 16.0 12.6 12.6
PI, ratio of LD50 between OP with antidote and OP given alone. MDP, highest multiple of the OP LD50 counteracted by the oximes. a i.p. LD50 of ATR-
4-OX = 10 mg/kg, HI-6 = 635.2 mg/kg, TMB-4 = 73.5 mg/kg. b s.c. LD50 of soman was 126 µg/kg. c s.c. LD50 of tabun was 317.5 µg/kg. d s.c. LD50 of 
paraoxon was 864.3 µg/kg. e nd = could not be determined. f “-” = not performed.
Figure 2. Viability, apoptosis and necrosis in lymphocytes treated with ATR-4-OX without and 
with metabolic activation (S9) 
Three-hundred cells per sample per experimental point were scored. CON, negative control; (a) sig-
nificantly higher viability as compared to matched control sample (S9-CON); (b) significantly higher 
viability as compared to sample treated with higher concentration of conjugate in the presence of 
S9; c, significantly lower incidence of necrotic cells as compared to matched control sample (S9-
CON) (p<0.05, χ2 test).
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It should be mentioned that soman binds irreversibly to 
AChE within minutes of exposure, underscoring the im-
portance of immediate administration of an oxime (An-
tonijević & Stojiljković, 2007).
Evaluation of cell viability, apoptosis/necrosis mea-
surements and comet assays were performed to esti-
mate the potential cyto/genotoxic effects of the new 
compound in human peripheral lymphocytes. ATR-4-
OX did not significantly impair the viability of lymp-
hocytes in samples without metabolic activator S9 
or in samples treated in the presence of S9 (Fig. 2). 
However, in samples treated with ATR-4-OX admini-
stered at a concentration of 25 % LD50 with metabolic 
activation, slightly lower lymphocyte viability (92.34 %) 
was observed as compared to the sample treated wit-
hout S9 (95.67 %). The difference was principally due 
to a non-significant increase of apoptotic cells (5.33 % 
vs. 2.33 %). The conjugate applied at the lower dose 
with metabolic activation significantly increased lymp-
hocyte viability compared to the corresponding con-
trol sample (96.33 % vs. 90.67 %; P = 0.0049, χ2 test) 
and compared to the sample treated with the higher 
concentration (96.33 % vs. 92.34 %; P = 0.0341, χ2 test). 
Figure 3. DNA damage in lymphocytes treated with ATR-4-OX without and with metabolic activation (S9)
Three-hundred individual comets per sample were measured. CON, negative control; PC, positive control (cells treated with 100 mM hy-
drogen peroxide on ice for 10 min). Significantly increased values: *compared to matched negative control; (a) compared to matched 
sample treated with 5 % LD50; (b) compared to positive control. 
Table 3. Results of hOGG1-modified comet assay
Sample Parameter
– S9 + S9
Flare buffer hOGG1 Oxidative  damage Flare buffer hOGG1
Oxidative  
damage
Negative 
control
Tail length 
Tail intensity
11.34 ± 0.32
0.43 ± 0.19
12.09 ± 0.32
0.59 ± 0.25
0.75
0.16
11.08 ± 0.13
0.59 ± 0.12
11.74 ± 0.12
0.86 ± 0.20
0.62
0.27
H2O2 
10 mM
Tail length 
Tail intensity
21.21 ± 0.75
12.20 ± 1.42
28.03 ± 1.30
22.61 ± 2.46
6.82b
10.41b
/
/
/
/
/
/
ATR-4–OX 
25 % LD50
Tail length 
Tail intensity
12.02 ± 0.19
0.84 ± 0.17
12.26 ± 0.22
1.25 ± 0.22
0.24
0.41
12.62 ± 0.28
1.44 ± 0.42
13.02 ± 0.21
1.57 ± 0.31
0.40
0.13
ATR-4–OX
5 % LD50
Tail length 
Tail intensity
11.96 ± 0.12
0.55 ± 0.08
13.20 ± 0.50
2.40 ± 0.86
1.24a
1.85a,c
11.76 ± 0.12
0.29 ± 0.05
12.95 ± 0.16
1.02 ± 0.13
1.19
0.73
One hundered individual comets per experimental point were measured. Tail length (μm) and tail intensity ( %) are expressed as mean values  ± 
S.E.M. Oxidative damage calculated by subtracting the means for tail length and intensity obtained by buffer treatment from the corresponding 
means obtained by enzymatic treatment. Statistics: ap<0.05 and bp<0.01 compared to the control; cp<0.05 compared to the treatment with S9.
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Moreover, the conjugate applied at the lower dose 
with metabolic activation significantly decreased the 
incidence of necrotic cells as compared to the corres-
ponding control sample (1.00 % vs. 3.66 %, P = 0.0305, 
χ2 test) (Fig. 2). In the alkaline comet assay, both te-
sted concentrations evoked an increase in tail intensity 
compared to the negative control, though the values 
recorded in different samples incubated with and wi-
thout metabolic activation did not differ significantly 
(Fig. 3). Mean tail intensity measured in the sample 
treated with the lower concentration of the conjugate 
without S9 was 3.86 ± 2.53 % vs. 4.88 ± 4.12 % in the 
sample treated with S9. Mean tail intensity measured 
in the sample treated with the higher concentration 
of the conjugate without S9 was 9.06 ± 4.76 % and 
9.43 ± 4.66 % in the sample treated with S9. Results 
of the neutral comet assay show that treatment with 
the oxime at both tested concentrations did not si-
gnificantly influence the integrity of lymphocyte DNA 
(Fig. 3). Since the hOGG1-modified comet assay re-
presents the most sensitive modification of the assay, 
which allows the detection of oxidative DNA damage, 
we also employed this test to evaluate whether ATR-
4-OX treatment produced this type of DNA damage. 
A significant level of 8-OhdG, which corresponded to 
1.24 µm for tail length and 1.85 % for tail intensity, 
was detected only at 5 % LD50 of the conjugate ad-
ministered without metabolic activation. This qualifies 
the induced oxidative damage as biologically irrelevant 
(Collins, 2004), since the corresponding values mea-
sured in the sample treated with H2O2 were 6.82 µm 
for tail length and 10.41 % for tail intensity (Table 3). 
Furthermore, these results suggest that the DNA le-
sions detected by the alkaline comet assay are not me-
diated by oxidative stress induction. Taken together, 
the findings of this study indicate an acceptable geno-
toxic profile of ATR-4-OX assessed on human lymp-
hocytes.
In conclusion, it seems that ATR-4-OX has a the-
rapeutic effect that is related to the reactivation of 
phosphylated AChE but not to receptor antagonizati-
on. Based on the obtained results, we are aware that 
a compound with such a high acute toxicity compa-
red to the currently used oximes has no future as an 
antidote in organophosphorus compounds poisoning. 
However, its acceptable cytotoxic and genotoxic profi-
les suggest that ATR-4-OX might be used as a source 
molecule for further development. Therefore, even if 
this conjugated compound has its limitations, the con-
cept of creating a bifunctional antidote should not be 
completely discarded. 
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